<DOC>
	<DOCNO>NCT00002878</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Some tumor become resistant chemotherapy drug . Combining PSC 833 chemotherapy may reduce resistance drug , allow tumor cell kill . It yet know whether combination chemotherapy plus PSC 833 effective combination chemotherapy alone treat patient relapsed refractory multiple myeloma . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without PSC 833 treat patient relapsed refractory multiple myeloma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without PSC 833 Treating Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival objective response rate patient relapse refractory multiple myeloma treat vincristine , doxorubicin , dexamethasone ( VAD ) without PSC 833 . - Compare event free survival subjective response patient treat regimen . - Correlate treatment outcome p-glycoprotein expression . - Determine whether prognostic factor previously determine useful untreated patient ( i.e. , plasma cell label index multidrug resistance determine bone marrow aspirate , serum beta 2-microglobulin interleukin-6 receptor level ) correlate objective subjective response event-free overall survival patient treat regimen . - Compare toxicity VAD without PSC 833 . OUTLINE : This randomize , multicenter study . Patients stratify response prior treatment , prior doxorubicin and/or vincristine , prior autologous peripheral blood stem cell transplantation , center . Patients randomize 1 2 treatment arm : - Arm I : The first group receive vincristine , doxorubicin , dexamethasone ( VAD ) . Patients receive high dose vincristine IV 96 hour higher dose doxorubicin IV 96 hour day 1-4 oral dexamethasone daily day 1-4 15-18 . - Arm II : The second group receive VAD plus oral PSC 833 . Patients receive oral PSC 833 every 6 hour begin day 1 continue 20 dos . Patients receive low dose vincristine IV 96 hour low dose doxorubicin IV 96 hour day 2-5 oral dexamethasone daily day 2-5 16-19 . Treatment arm repeat every 4 week absence disease progression unacceptable toxicity . After completion 2 course , patient reevaluate , stable respond disease continue treatment 2 course beyond maximum response . Doxorubicin discontinue patient receive maximum lifetime dose still stable respond disease . Patients follow every 2 month survival . PROJECTED ACCRUAL : A total 360 patient accrue study approximately 20 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Multiple myeloma stage confirm : Bone marrow plasmacytosis least 10 % plasma cell , sheet plasma cell , biopsy proven plasmacytosis Myeloma ( M ) protein serum and/or urine Measurable disease least one following : Serum Mcomponent least 1.0 g/dL electrophoresis Baseline measurement nephelometry also , use follow response Urine Mprotein excretion great 200 mg/24 hour electrophoresis The following consider measurable follow response : Lytic bone lesion Bone marrow plasmacytosis Anemia Serum beta 2microglobulin Objective evidence progression least one following : Increased serum Mprotein ( electrophoresis unless Mspike le 1.5 g/dL ) At least 50 % low remission level least 2 g/dL To 1.0 g/dL sole protein indication relapse Nephelometry may use instead electrophoresis Increased urine Mprotein To 50 % low level OR 2 g/24 hour To great 200 mg/24 hour Definite new lytic bone lesion least 50 % increase size exist lesion ( discussion ECOG Study Chairman require sole indication progression ) Increase serum urine Mprotein 25 % 50 % ( ) plus one following : Serum calcium great 12 mg/dL without cause Hemoglobin decrease 2.0 g/dL attribute chemotherapy , interferon therapy , myelodysplastic syndrome Less 11 g/dL men Less 10 g/dL woman At least 50 % increase bone marrow plasmacytosis Failure prior cytotoxic therapy define one following : Never respond Relapsed within 2 month last treatment Relapsed 212 month last treatment follow initial response Adequate prior chemotherapy require , e.g . : At least 2 course combination chemotherapy ( e.g. , VBMCP , VBAP , MP ) Prior vincristine , doxorubicin , dexamethasone ( VAD ) allow No demonstrate resistance VAD At least 3 month since prior VAD Cumulative doxorubicin dose 250 mg/m2 Prior autologous peripheral blood stem cell transplant allow perform prior development drug resistance No prior allogeneic transplant No smoldering myeloma , localize plasmacytoma , monoclonal gammopathy undetermined significance ( MGUS ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 03 Life expectancy : At least 2 month Hematopoietic : Absolute neutrophil count least 1,000/mm^3 Platelet count least 50,000/mm^3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) AST le 1.5 time ULN No chronic active hepatitis cirrhosis Renal : Creatinine le 3.0 mg/dL Cardiovascular : Ejection fraction least 50 % No history congestive heart failure No overt angina despite medication No myocardial infarction within 2 month No poorly control hypertension ( i.e. , pressure 200/110 high despite medication ) No arrhythmia require therapy ( i.e. , sustain atrial ventricular arrhythmia multifocal premature ventricular contraction ) Digoxin control ventricular rate atrial fibrillation chronic 1 month allow Neurologic : No peripheral neuropathy weakness No cerebellar disease ataxia Gastrointestinal : Adequate gastrointestinal function allow absorption PSC 833 No active peptic ulcer Other : No hypersensitivity PSC 833 cyclosporine No active infection HIV negative No uncontrolled diabetes mellitus No second malignancy within past 5 year except curatively treat nonmelanomatous skin cancer , carcinoma situ cervix , localized cancer treat surgery alone Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious medical problem unless sufficiently stabilize PRIOR CONCURRENT THERAPY : Biologic therapy : Prior biologic therapy ( e.g. , interferon ) allow Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( include plicamycin ) Endocrine therapy : At least 2 week since high dose steroid ( least 100 mg/m2/day prednisone least 40 mg/day dexamethasone ( include steroid hypercalcemia ) Radiotherapy : At least 2 week since prior radiotherapy except limited radiotherapy single bone lesion Surgery : At least 4 week since prior major surgery Other : No concurrent anticoagulants No concurrent drug know modulate cyclosporine blood concentration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>refractory multiple myeloma</keyword>
</DOC>